Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT03524391 Completed - Prostate Cancer Clinical Trials

Effect of Yoga Counselling on Quality of Life and Psychological Outcomes of Prostate Cancer Patients

Start date: February 12, 2016
Phase: N/A
Study type: Interventional

Cancer is second leading cause of death worldwide. The psychological issues are related to all stages of the disease affecting outcome of treatment and overall quality of life. The study evaluated the effectiveness of yoga counselling among prostate cancer patients on their quality of life and psychological outcomes.

NCT ID: NCT03447028 Completed - Prostate Cancer Clinical Trials

Effect of TyG Index on Outcomes of Radical Prostatectomy

TyG-PCa
Start date: January 1, 2007
Phase: N/A
Study type: Observational [Patient Registry]

We investigate the association between Triglyserid-Glucose(TyG) index and prostate cancer in patients undergoing radical prostatectomy.

NCT ID: NCT03423927 Completed - Prostate Cancer Clinical Trials

Benefits of an Intervention Combining Hypnosis and Self-care for Prostate Cancer Patients

Start date: October 14, 2013
Phase: N/A
Study type: Interventional

This study aims to assess the impact of a group intervention combining self-hypnosis and self-care techniques on prostate patients' well-being. More specifically, the investigators want to investigate the effects of that intervention on sleep, fatigue and emotional distress of the patients.

NCT ID: NCT03410641 Completed - Prostate Cancer Clinical Trials

Long-term Cancer Risk in the Randomised Oslo Diet and Antismoking Study

Start date: January 15, 1972
Phase: N/A
Study type: Observational

This study examines the effect of a five-year multifactorial lifestyle intervention in the Oslo diet and antismoking study on long-term cancer risk. In 1972-1973, 1232 men with high cardiovascular risk profile were randomised to intervention including cholesterol lowering diet, weight loss and antismoking advice, or control (1:1). This study examines the effect of the intervention on 43-year cancer incidence and mortality.

NCT ID: NCT03376360 Completed - Prostate Cancer Clinical Trials

Functional Medical Imaging Quantization in Prostate Cancer

QUIP
Start date: October 1, 2015
Phase: N/A
Study type: Observational

Prostate cancer is the most common cancer in men over 50 years old and the third leading cause of cancer death. Because of the variety of prostate cancers, different treatments exist. Several criteria guide this management in daily practice: PSA level; TNM stage (digital rectal examination, trans-rectal ultrasound and classical visual imaging) and pathological differentiation with the Gleason score, to which can be added other prognostic criteria: growth and doubling time of the serum PSA, number of positive biopsies and percentage of cancer lesions by biopsy. Functional imaging by PET and MRI is increasingly used in daily clinical practice to characterize prostate cancer, either during initial discovery or during recurrence. In this context, it is the qualitative visual analysis that is mainly used. Quantitative image analysis could add new criteria to guide patient management. Consequently, the objective of this study were: - Optimization of 18F-choline PET/CT Acquisition in Prostate Cancer - Comparison the quantitative parameters obtained by 18F-Choline PET / CT and both perfusion MRI and histological parameters.

NCT ID: NCT03339531 Completed - Prostate Cancer Clinical Trials

Optimized 2D-RT for Prostate Cancer

Start date: February 2, 2015
Phase: N/A
Study type: Interventional

Prostate cancer (CAP) is one of the most common malignancies in men, both in Western countries and developing countries. Radiation therapy (RT) is an important therapeutic option. New technologies (3D, IMRT, IGRT, VMAT) have been introduced in the last decades, with a progressive improvement of clinical outcome. However, in many countries the only treatment option is the traditional 2D technique based on standard simulation. The indications for field definition in this treatment are still based on expert's opinions. The aim of this analysis is to propose new indications for 2D fields definition based on three-dimensional simulation in a population of patients with CAP. Twenty patients with CAP consecutively treated with RT in our center were identified. Patients underwent CT-simulation in supine position. Pelvic MRI images were fused with CT-simulation images. In this way, delineation of the prostate and seminal vesicles was performed on MRI images. Clinical Target Volume definition (CTV) was performed according to EORTC guidelines simulating 4 different categories: low-risk CAP, intermediate-risk CAP, high-risk CAP without involvement of the seminal vesicles, and high-risk CAP with involvement of seminal vesicles. The Planning Target Volume (PTV) was defined by adding a margin of 10 mm to the CTV in all directions. For each patient, 8 treatment plans were calculated. In particular, for each of the 4 categories of risk, 2 treatment plans were calculated by using a cobalt source or 10 MV photons. Treatment plans were calculated using the box technique. Progressive optimization was realized with an iterative procedure by evaluating the three-dimensional dose distribution. Once the final plan was achieved (respecting the PTV constraint: D98 > 95%), distances of the fields edges from a set of reference points were measured.

NCT ID: NCT03331068 Completed - Prostate Cancer Clinical Trials

French Validation of the Memorial Anxiety Scale for Patients With Prostate Cancer.

Start date: April 26, 2016
Phase: N/A
Study type: Observational

A specific scale allowing the measure of anxiety of patients with protate cancer has been designed and validated but the French version needs to be validated. This study aims at validating the French translation of this scale.

NCT ID: NCT03321149 Completed - Prostate Cancer Clinical Trials

Reducing Sedentary Behavior Among Prostate Cancer Survivors on Androgen Deprivation Therapy

RiseTx
Start date: July 1, 2015
Phase: N/A
Study type: Interventional

The current study aimed to develop and assess an easy-to-use, highly accessible mobile and web-based application intervention to reduce sedentary behavior and increase physical activity in the hope of reducing the side effects of treatment and improving quality of life for the 13,000 or more prostate cancer survivors who are prescribed ADT each year in Canada. The study was conducted in two phases, where Phase one was focused on finding out about the attitudes and perceptions of sedentary behavior and the use of mobile applications among prostate cancer survivors using semi-structured interviews. Together with professional experts and a group of men who were diagnosed with prostate cancer, we developed RiseForTx - an application that is used on a smartphone or tablet to reduce time spent in, and to change patterns of, sedentary behaviour each day (Phase two). Part of the intervention was also focused on increasing daily steps to improve physical activity. We tested the intervention to examine (i) how the application works, (ii) if prostate cancer survivors like it and use it; and (iii) if sedentary behaviour and physical activity can reduce the impact of the side effects for treatment and improve quality of life among men on ADT.

NCT ID: NCT03315585 Completed - Prostate Cancer Clinical Trials

The Efficacy and Safety of Composite Steep-pulse Treatment Apparatus Used in Prostate Cancer Focal Therapy

Start date: April 27, 2017
Phase: N/A
Study type: Interventional

This trial is studying the effects and safety in treating patients with local prostate cancer with a new IRE device called Composite Steep-pulse Treatment Apparatus. This new device could cause cell irreversible electroporation, which leading necrosis of tumor cells. It also has the ability to prevent nerve,vessel, urethral and capsule unnecessary injury beside the ablation area. Composite Steep-pulse Treatment Apparatus will be used in patients who pass inclusion/exclusion criteria. Safety, quality of life, and histopathological analysis of prostate speciem will be evaluated in each study patients.

NCT ID: NCT03297385 Completed - Prostate Cancer Clinical Trials

Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen Ablation

DARANA
Start date: August 28, 2014
Phase: Phase 2
Study type: Interventional

Rationale: Understanding the mechanisms of enzalutamide as an androgen receptor inhibitor in early prostate cancer could lead to improved patient selection for treatment. Objective: To study the effects of enzalutamide on surgical margin status and AR / DNA interaction and gene expression. Intervention : Men with localized prostate cancer will undergo an additional set of targeted tumor biopsies and will be subsequently treated with 3 months of enzalutamide. The prostatectomy specimen will be additionally sampled, ex vivo.